Getinge reaffirms 2026 outlook, launches Cardiohelp II platform

Getinge AB reaffirmed its 2026 financial outlook targeting 3-5% organic net sales growth despite headwinds from weak pharmaceutical spending in its Life Science segment. It reported SEK 45 million in tariff refunds and about SEK 36 million from currency effects, and launched its Cardiohelp II ECLS platform in CE-marked countries and Hong Kong.

Detected & updated continuously · Source: Nebula